Fetal embolization trial moves severe vein of Galen malformation treatment into the prenatal window
A first-in-kind feasibility study is set to test whether a severe vein of Galen malformation can be embolized before birth, using a laparotomy-assisted fetal approach designed to reach the intracranial vascular lesion through transuterine cardiac access. The protocol, titled FETTUS for Fetal Embolization Via Transcardiac Transarterial Ultrasound and Fluoroscopy-guided Endovascular Surgery, is built around a narrow clinical premise: some fetuses with the most aggressive forms of VOGM deteriorate so early and so severely that waiting until delivery may leave too little physiologic reserve for survival.
The study plans to enroll 10 participants and is not yet recruiting. Investigators are targeting maternal, fetal, neonatal, and infant outcomes over a long follow-up period that extends to 24 months of age. The primary intent is feasibility and safety, not efficacy proof in the conventional randomized-trial sense. Even so, the clinical logic is clear. By reducing the shunt burden before birth, the procedure aims to blunt the cascade of high-output cardiac failure, hydrops, and progressive cerebral injury that can accompany severe VOGM.
How the fetal procedure is designed to reach the brain lesion
The operative plan adapts techniques already used in complex fetal surgery. During the procedure, the mother’s uterus is exteriorized through a standard laparotomy approach, then transuterine fetal cardiac access is obtained under continuous ultrasound guidance. Once the needle is positioned, a microcatheter is advanced through the fetal vascular system to the malformation in the brain. The malformation is then embolized with Trufill n-BCA Liquid Embolic System, a medical-grade glue intended to occlude the abnormal vascular channels.
A single sentence captures the procedural ambition: the target is a deep brain vascular lesion reached before delivery through the fetal heart.
This is not a casual technical extension of postnatal embolization. Fetal intervention carries a different risk profile because maternal anesthesia, uterine manipulation, membrane integrity, fetal hemodynamics, and placental physiology all become part of the safety equation at once. The protocol therefore limits eligibility to pregnancies in which the fetus shows severe imaging features but still appears salvageable enough to justify intervention. Follow-up ultrasound scans and consultations are planned after surgery, and delivery is scheduled at Texas Children’s Hospital.
Imaging thresholds define a very high-risk fetal population
The eligibility criteria are unusually specific, and for good reason. The trial is not meant for all fetal VOGM cases. It is limited to singleton pregnancies in pregnant people aged 18 years or older with prenatal sonographic evidence of VOGM between 23 weeks 0 days and 37 weeks 0 days of gestation. Additional imaging criteria include a VOGM volume ratio greater than 9.69% and a narrowest mediolateral diameter of the straight or falcine sinus greater than 10.15 mm on prenatal MRI.
Progression matters as much as size. Candidates must also show worsening VOGM severity on serial imaging and exceed at least one prognostic threshold: VOGM varix volume of at least 10.9 cm3, new or progressive middle cerebral artery pseudofeeders, or worsening combined cardiac index above 750 mL/kg/min. These markers point to a lesion that is not merely present, but biologically active and hemodynamically consequential.
The exclusion criteria draw a hard line around irreversible injury. Extensive fetal brain parenchymal injury or gliosis involving more than one quarter of supratentorial brain volume excludes participation, as does severe hydrops fetalis, defined by large-volume effusions with organ compression, diffuse skin edema, and marked cardiomegaly. The protocol also excludes major placental abnormalities, significant maternal surgical risk, and low amniotic fluid when it appears linked to fetal anomaly, poor placental function, or membrane rupture.
Maternal safety constraints remain central to the trial design
The maternal side of the equation is tightly regulated. Participants must have negative serologic tests for HIV, hepatitis B, and hepatitis C because of the increased transmission risk during maternal-fetal surgery. They must also have declined termination of pregnancy, meet psychosocial criteria, and sign informed consent together with the father of the baby.
The exclusion list shows how much the investigators are trying to reduce avoidable harm. Prior hysterotomy in an active uterine segment, severe obesity with pre-pregnancy BMI of 40 or higher, technical barriers such as extensive fibroids or membrane separation, Rh alloimmunization, significant medical illness classified as ASA Physical Status III or higher, and hypersensitivity to either the nonionic contrast agent or the liquid embolic system all remove a patient from consideration. Severe depression without psychiatric clearance also excludes participation, as does inability to comply with travel and follow-up requirements.
These are not administrative details. They reflect the reality that fetal endovascular surgery sits at the intersection of maternal-fetal medicine, pediatric neurosurgery, interventional radiology, and anesthesiology. A complication in any one domain can rapidly become a complication in all of them.
Why prenatal embolization could matter in severe VOGM
Severe VOGM is a rare congenital vascular malformation with potentially lethal consequences. The lesion creates abnormal arteriovenous shunting that can overwhelm the fetal and neonatal cardiovascular system. In the most advanced cases, the result is progressive cardiac stress, heart failure, hydrops, and brain injury before the infant is even born. Standard postnatal embolization remains the established treatment pathway, but some fetuses may deteriorate too far before delivery for a postnatal rescue strategy to be effective.
Prenatal embolization is an attempt to intervene earlier in that trajectory. By reducing the shunt while the circulatory system is still fetal, the approach could theoretically protect the heart and preserve cerebral perfusion long enough to improve postnatal survival and limit neurologic injury. The pathophysiology supports the concept, but the bar for proving net benefit is high because the procedure itself introduces maternal surgical risk and fetal procedural risk.
The planned 24-month infant follow-up is especially important. In severe VOGM, survival alone is not the only endpoint that matters. Neurodevelopment, ongoing vascular stability, and the need for additional procedures will determine whether prenatal treatment meaningfully changes the long arc of disease.
A small cohort with a long clinical horizon
Enrollment is estimated at 10, with study start projected for March 2027, primary completion in December 2032, and final completion in December 2035. Those dates signal a deliberately cautious development path. This is not a large trial, and it cannot answer every question about comparative effectiveness. It is designed to establish whether the fetal approach can be performed with acceptable maternal and fetal safety in a highly selected group of pregnancies.
The study is being led from Texas Children’s Hospital in Houston, with Michael A. Belfort listed as sponsor and responsible party. The investigative team includes specialists across maternal-fetal medicine, pediatric surgery, neurosurgery, radiology, and anesthesia, which fits the complexity of the intervention itself.
For severe VOGM, the unanswered question is not whether the lesion is dangerous. The danger is already built into the diagnosis. The unresolved issue is whether moving embolization into fetal life can alter a condition that often accelerates faster than delivery can keep up. This study is built to find out whether that shift is technically possible, physiologically tolerable, and safe enough to justify the next step in a rare and high-stakes disease.